Table 1 Characteristics of CD20×CD3 bispecifc antibodies
Agent | Format | CD20:CD3 ratio | Administration | FC silencing mutations | Dosing | Approved indications |
|---|---|---|---|---|---|---|
Epcoritamab1 | IgG1 | 1:1 | SC | L234F, L235E, D265A (no FcγR, C1q binding) | Step-wise | LBCL and FL R/R after 2 or more lines |
Glofitamab2 | IgG1 | 2:1 | IV | IgG1-P329G-LALA (no FcγR binding) | Step-wise | LBCL after 2 or more lines |
Odronextamab5 | IgG4 | 1:1 | IV | Modified IgG4 (no FcγRIII binding) | Step-wise | Non approved for now |
Mosunetuzumab12 | IgG1 | 1:1 | IV/SC | N297G (no FcγR binding) | Step-wise | R/R FL after 2 or more lines |
Plamotamab8 | IgG1 | 1:1 | IV/SC | G236R, L328R (no FcγR binding) | Step-wise | Non approved for now |